非酒精性脂肪肝病患者的饮食和运动管理研究进展

张文, 房丽, 牛海艳

武警医学 ›› 2019, Vol. 30 ›› Issue (10) : 913-916.

PDF(716 KB)
PDF(716 KB)
武警医学 ›› 2019, Vol. 30 ›› Issue (10) : 913-916.
综述

非酒精性脂肪肝病患者的饮食和运动管理研究进展

  • 张文, 房丽(综述),牛海艳(审校)
作者信息 +
文章历史 +

摘要

非酒精性脂肪肝病(nonalcoholic fatty liver disease,NAFLD),是指在除外酒精和其他明确的损肝因素所致的肝细胞内脂肪过度沉积为主要特征的临床病理综合征[1],是与胰岛素抵抗和遗传易感性密切相关的获得性代谢应激性肝损伤。NAFLD的疾病谱主要包括单纯性脂肪肝、非酒精性脂肪性肝炎(NASH)、NASH肝硬化,最终可能进展为肝细胞癌(HCC)[2]。目前,NAFLD已成为全球慢性肝病的主要病因,在西方国家发病率为20%~30%,主要与久坐、运动量少等生活方式,以及不适当的饮食习惯有关[3]。研究表明,占80%的美国人都患有肥胖症,其中三级肥胖体重指数(BMI>40 kg/m2)人群中NAFLD发病率为90%,而NASH发病率为2%~3%[4]。此外,NAFLD在糖尿病患者中非常普遍,2型糖尿病发展为NAFLD、NASH和晚期NASH的风险较高,进展到肝纤维化,肝细胞癌时肝脏相关的死亡风险增加[5]。而目前对于NAFLD的治疗,主要仍是以生活干预为基础的方案,笔者对NAFLD患者的饮食及运动疗法等非药物治疗方式进行综述。

关键词

脂肪肝 / 营养状况 / 身体活动锻炼

引用本文

导出引用
张文, 房丽, 牛海艳. 非酒精性脂肪肝病患者的饮食和运动管理研究进展[J]. 武警医学. 2019, 30(10): 913-916
中图分类号: R575.5   

参考文献

[1] 冯 巩, 贺 娜, 王菊宁,等. 非酒精性脂肪性肝病的流行病学与血清无创诊断研究进展[J]. 中华肝脏病杂志, 2018, 26(6):476-480.
[2] Castera L, Friedrich-Rust M, Loomba R,et al. Noninvasive assessment of liver disease in patients with nonalcoholic fatty Liver disease[J].Gastroenterology, 2019, 156: 1264-1281, e4.
[3] Schwimmer J, Ugalde-Nicalo P, Welsh J, et al. Effect of a low free sugar diet vs usual diet on nonalcoholic fatty liver disease in adolescent boys: a randomized clinical trial[J].JAMA, 2019, 321(3): 256-265.
[4] Bellentani S, Scaglioni F, Marino M, et al. Epidemiology of Non-Alcoholic fatty liver disease[J]. Digest Dis, 2010, 28(1):155-161.
[5] 魏 燕, 杨 阳, 王 赭,等. 无肝硬化乙肝患者肝癌发病影响因素分析[J]. 武警医学, 2017, 28(6):564-566.
[6] Day C P, James O F. Steatohepatitis: a tale of two "hits"[J]. Gastroenterology, 1998,114(4):842.
[7] Feldstein A E. Novel insights into the pathophysiology of nonalcoholic fatty liver disease[J]. Semin Liver Dis, 2010,30(4):391.
[8] Georgoulis M, Fragopoulou E, Kontogianni M D, et al. Blood redox status is associated with the likelihood of nonalcoholic fatty liver disease irrespectively of diet’s total antioxidant capacity[J]. Nutr Res, 2015,35(1):41-48.
[9] 丁玉平, 李 海, 张 文, 等. ALT升高的非酒精性脂肪性肝病的流行病学特征及其危险因素分析[J]. 临床肝胆病杂志, 2017,33: 2355-2360.
[10] Moschen A R, Tilg H. Nutrition in pathophysiology and treatment of nonalcoholic fatty liver disease[J]. Current Opinion in Clinical Nutrition and Metabolic Care, 2008, 11(5):620-625.
[11] Rahman V J. Low-fat vs low-carbohydrate diets and weight loss.[J]. JAMA, 2018, 320(2):202-204.
[12] Ohashi T, Kato M, Yamasaki A, et al. Effects of high fructose intake on liver injury progression in high fat diet induced fatty liver disease in ovariectomized female mice[J]. Food & Chemical Toxicology, 2018, 118:190-197.
[13] 常 越, 李 海. 肠道菌群与非酒精性脂肪性肝炎发生发展的关系[J]. 临床肝胆病杂志, 2018, 34(6):1343-1346.
[14] Kargulewicz A, Stankowiak-Kulpa H, Marian G. Dietary recommendations for patients with nonalcoholic fatty liver disease[J]. Gastroenterology Review, 2014, 9(1):18-23.
[15] Kwok R, Choi K C, Wong L H, et al. Screening diabetic patients for non-alcoholic fatty liver disease with controlled attenuation parameter and liver stiffness measurements: a prospective cohort study[J]. Gut, 2016,65(8):1359-1563.
[16] Westerbacka J, Lammi K, HKkinen A M, et al. Dietary fat content modifies liver fat in overweight nondiabetic Subjects[J]. J Clin Endocrinol & Metab, 2005, 90(5):2804-2809.
[17] Ratziu V, Ghabril M, Romero M, et al. Recommendations for management and treatment of nonalcoholic steatohepatitis[J]. Transplantation, 2019, 103(1):28-42.
[18] Association A D, Bantle J P, Wylierosett J, et al. Nutrition recommendations and interventions for diabetes: a position statement of the American Diabetes Association[J]. Diabetes Care, 2007, 30(4):S48.
[19] European Association for Cardiovascular Prevention & Rehabilitation.‘Ten Commandments’from the 2016 ESC/EAS Guidelines for the management of dyslipidaemias[J]. Eur Heart J, 2011, 37(39):2966.1-2966.
[20] Marchesi J R, Adams D H, Fava F, et al. The gut microbiota and host health: a new clinical frontier[J]. Gut, 2016, 65(2):330-339.
[21] Imajo K, Yoneda M, Ogawa Y, et al. Microbiota and nonalcoholic steatohepatitis[J]. Seminars in Immunopathol, 2014, 36(1):115-132.
[22] Mahady S E, Wong G, Craig J C, et al. Pioglitazone and vitamin E for nonalcoholic steatohepatitis: A cost utility analysis[J]. Hepatology, 2012, 56(6):2172-2179.
[23] Chalasani N, Younossi Z, Lavine J E, et al. The diagnosis and management of non-alcoholic fatty liver disease: Practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association[J]. Hepatology, 2012, 55(6):2005-2023.
[24] Seitz H K, Mueller S, Hellerbrand C, et al. Effect of chronic alcohol consumption on the development and progression of non-alcoholic fatty liver disease (NAFLD)[J]. Hepatobiliary Surgery & Nutrition, 2015, 4(3):147-151.
[25] 贾国瑜, 韩 涛, 高 磊, 等. 有氧运动和抗阻运动改善非酒精性脂肪肝的随机对照研究[J]. 中华肝脏病杂志, 2018, 26(1):34-43.
[26] Dubé J J, Amati F, Stefanovic-Racic M, et al. Exercise-induced alterations in intramyocellular lipids and insulin resistance: the athlete’s paradox revisited[J]. Am J Physiol Endocrinol Metab, 2008,294(5):E882
[27] Linden M A, Sheldon R D, Meers G M, et al. Aerobic exercise training in the treatment of non-alcoholic fatty liver disease related fibrosis[J]. J Physiology, 2016, 594(18):5271-5277.
[28] Oh S, Tanaka K, Warabi E. Exercise reduces inflammation and oxidative stress in obesity-related liver diseases[J]. Med Sci Sports Exerc, 2013,45(12):2214-2218.
[29] Kowdley K V, Belt P, Wilson L A, et al. Serum ferritin is an independent predictor of histologic severity and advanced fibrosis in patients with nonalcoholic fatty liver disease[J]. Hepatology, 2012, 55(1):77-85.

PDF(716 KB)

Accesses

Citation

Detail

段落导航
相关文章

/